A synthetic peptide from aa region 80-130 of human OLIG2 conjugated to blue carrier protein was used as the antigen. The peptide is homologous in rat and mouse.
OLIG2
Reaktivität: Human
WB, IHC
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
A concentration of 10-50 µg/ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Reconstitute in 100 µL of sterile water. Centrifuge to remove any insoluble material.
Handhabung
Avoid freeze and thaw cycles.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.
Function: Required for oligodendrocyte and motor neuron specification in the spinal cord, as well as for the development of somatic motor neurons in the hindbrain. Cooperates with OLIG1 to establish the pMN domain of the embryonic neural tube. Antagonist of V2 interneuron and of NKX2-2-induced V3 interneuron development. Subcellular location: Nucleus. Cytoplasm Tissue specificity: Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas highly variable. Involvement in disease: A chromosomal aberration involving OLIG2 may be a cause of a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(14,21)(q11.2,q22) with TCRA. Also known as: Basic helix loop helix protein class B 1, BHLHB1, olig2, OLIGO2, Oligodendrocyte specific bHLH transcription factor 2, Oligodendrocyte transcription factor 2, PRKCBP2, Protein kinase C binding protein 2, Protein kinase C binding protein RACK17, RACK17.